Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association [0.03%]
成人T细胞白血病/淋巴瘤与EB病毒阳性DLBCL：一种罕见的并存关联
Viola Maria Popov,Diana Grasu,Horia Bumbea et al.
Viola Maria Popov et al.
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive lymphoma with a poor prognosis. The human T-lymphotropic virus 1 (HTLV-1) is associated with immunodeficiency and increased extranodal involvement in patients with diffuse large B-cell ...
Yan Leyfam
Yan Leyfam
Yan Leyfman, MD, reflected on resilience and hope in the face of cancer, recounting a 37-year-old diagnosed with stage IV colorectal cancer followed by HIV.
Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study [0.03%]
术前单药阿霉素新辅助化疗治疗可切除的II/III期软组织肉瘤：一项回顾性研究
Shiny Chih-Hsuan Wu,Yao-Yu Wu,Chi-Ting Liau et al.
Shiny Chih-Hsuan Wu et al.
Background: Soft tissue sarcomas (STS) are rare but aggressive tumors. Although surgery and radiotherapy are standard treatments for localized STS, the role of adjuvant chemotherapy, particularly doxorubicin, in high-grad...
A Multicenter Quality Audit Standardizing Esophageal Contouring in Postmastectomy Radiotherapy [0.03%]
多中心质量审核规范乳腺切除术后放射治疗的食管勾画
Manjinder Singh Sidhu,Deepak Abrol,Mohan Lal et al.
Manjinder Singh Sidhu et al.
Background: Postmastectomy radiotherapy (PMRT) delivered with volumetric modulated arc therapy (VMAT) often results in higher esophageal doses than 3D techniques. Recent dose-toxicity studies recommend limiting the esopha...
Multicenter Study
Oncology (Williston Park, N.Y.). 2026 Mar 16;40(2):10-14. DOI:10.46883/2026.25921068 2026
Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer [0.03%]
不可手术的野生型非小细胞肺癌使用化疗联合三种最常用的PD-1抑制剂的对比研究
Dapeng Wu,Juanjuan Cui,Wenjing Zhum et al.
Dapeng Wu et al.
Objective: Immunotherapy combined with chemotherapy is a standard treatment for advanced non-small cell lung cancer (NSCLC). However, the comparative efficacy and safety of cost-efficient modified PD-1 inhibitors remain i...
Comparative Study
Oncology (Williston Park, N.Y.). 2026 Mar 16;40(2):123-133. DOI:10.46883/2026.25921065 2026
Exploring the Influencing Factors of Quality of Life During Maintenance Phase in Patients With Breast Cancer-Related Lymphedema [0.03%]
乳腺癌术后淋巴水肿维持期患者生活质量影响因素探讨
Zebing Luo,Manjia Xu,Shuxian Yu et al.
Zebing Luo et al.
Purpose: This study aims to understand the degree of influence of the severity of lymphedema on quality of life (QOL) in patients with breast cancer-related lymphedema (BCRL) during the maintenance phase, and to understan...
Yan Leyfman
Yan Leyfman
What is Humanities in Medicine? ONCOLOGY dives beyond clinical metrics of survival rates and molecular pathways and explores the narrative medicine of diagnosis, the ethical complexities of end-of-life care, and the psychological impact of ...
2025 Report on the Mantle Cell Lymphoma Scientific Consortium and Workshop Hosted by the Lymphoma Research Foundation [0.03%]
2025年淋巴瘤研究基金会主办的套细胞淋巴瘤科学联盟和工作组报告
Lymphoma Research Foundation Lymphoma Research Foundation
Lymphoma Research Foundation Lymphoma Research Foundation
Mantle cell lymphoma (MCL) is a rare, aggressive form of non-Hodgkin lymphoma that arises from cells within the mantle zone (the outer ring of lymphocytes surrounding the center of a lymphatic nodule). Recent treatment advances, such as the...
Remote Exercise Program for Patients With Metastatic Renal Cell Carcinoma Undergoing Immunotherapy: An EXIO Case Series Report [0.03%]
转移性肾细胞癌免疫治疗患者的远程锻炼计划：EXIO案例系列报告
Paulo Gustavo Bergerot,Cristiane D Bergerot,Kathryn H Schmitz et al.
Paulo Gustavo Bergerot et al.
Background: Patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs), alone or in combination with tyrosine kinase inhibitors (TKIs), often experience significant treatment-rel...
Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard? [0.03%]
自体干细胞移植在多发性骨髓瘤中的地位仍是金标准吗？
Taha Kassim Dohadwala,Jenna Ghazal,Soumiya Nadar et al.
Taha Kassim Dohadwala et al.
Multiple myeloma, the second most common hematologic malignancy, accounts for approximately 10% of all blood cancers. Therapeutic advances have transformed multiple myeloma from a uniformly fatal disease into a chronic, manageable condition...